AKER vs. AWH, ICCC, ABIO, OCX, CDIO, VNRX, TRIB, TKNO, BMRA, and ACHV
Should you be buying Akers Biosciences stock or one of its competitors? The main competitors of Akers Biosciences include Aspira Women's Health (AWH), ImmuCell (ICCC), ARCA biopharma (ABIO), OncoCyte (OCX), Cardio Diagnostics (CDIO), VolitionRx (VNRX), Trinity Biotech (TRIB), Alpha Teknova (TKNO), Biomerica (BMRA), and Achieve Life Sciences (ACHV). These companies are all part of the "medical" sector.
Akers Biosciences (NASDAQ:AKER) and Aspira Women's Health (NASDAQ:AWH) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, community ranking, media sentiment, analyst recommendations, institutional ownership and risk.
Aspira Women's Health has a consensus price target of $4.45, indicating a potential upside of 38.63%. Given Aspira Women's Health's higher possible upside, analysts plainly believe Aspira Women's Health is more favorable than Akers Biosciences.
In the previous week, Aspira Women's Health had 2 more articles in the media than Akers Biosciences. MarketBeat recorded 2 mentions for Aspira Women's Health and 0 mentions for Akers Biosciences. Akers Biosciences' average media sentiment score of 0.00 beat Aspira Women's Health's score of -0.75 indicating that Akers Biosciences is being referred to more favorably in the media.
5.5% of Akers Biosciences shares are held by institutional investors. Comparatively, 12.2% of Aspira Women's Health shares are held by institutional investors. 0.3% of Akers Biosciences shares are held by insiders. Comparatively, 4.3% of Aspira Women's Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Akers Biosciences has higher earnings, but lower revenue than Aspira Women's Health.
Akers Biosciences has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500. Comparatively, Aspira Women's Health has a beta of 1.57, indicating that its stock price is 57% more volatile than the S&P 500.
Akers Biosciences received 294 more outperform votes than Aspira Women's Health when rated by MarketBeat users. Likewise, 72.92% of users gave Akers Biosciences an outperform vote while only 30.23% of users gave Aspira Women's Health an outperform vote.
Akers Biosciences has a net margin of 0.00% compared to Aspira Women's Health's net margin of -176.74%. Akers Biosciences' return on equity of -87.42% beat Aspira Women's Health's return on equity.
Summary
Akers Biosciences beats Aspira Women's Health on 8 of the 15 factors compared between the two stocks.
Get Akers Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for AKER and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AKER and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Akers Biosciences Competitors List
Related Companies and Tools
